Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Koffiekamer  /  Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)

Ontvang nu dagelijks onze kooptips!

word abonnee

Koffiekamer« Terug naar discussie overzicht

Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)

524 Posts
Pagina: «« 1 ... 22 23 24 25 26 27 »» | Laatste | Omlaag ↓
  7. Omnius 14 november 2016 11:39
    Laurent Levy, CEO of Nanobiotix, commented: “These exciting data show that NBTXR3 could be a potential game
    changer in Immuno-oncology combination landscape. This raises the possibility of synergies between NBTXR3,
    radiotherapy and immunotherapies. On the top of existing core developments of our product as a single agent, this is
    opening new doors for industrial collaborations.”
  12. Omnius 16 november 2016 10:15
    quote:

    Omnius schreef op 14 november 2016 09:53:

    www.nanobiotix.com/download/news_en/2...

    NANOBIOTIX PRESENTS NBTXR3 PRECLINICAL DATA DEMONSTRATING
    ITS POTENTIAL USAGE AS IN SITU VACCINE FOR CANCER
    AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING
    " First market approval has been filed in the EU and could be obtained in 2017."


  14. Omnius 15 december 2016 09:05
    www.proactiveinvestors.co.uk/companie...

    Nanobiotix reports excellent results from early stage liver cancer trial
    Share
    07:46 15 Dec 2016
    The nanopaticles were administered by intra-tumoural (IT) injection and activated by high precision radiation therapy.
    picture of cancer cell
    Liver cancer is one of the hardest forms of the disease to treat
    Cancer treatment group Nanobiotix (EPA:NANO) has reported ‘excellent’ results from an early stage trial of its nanoparticle technology in liver cancer sufferers.

    The aim with trial with NBTXR3, one of seven Nanobiotix has ongoing in various types of cancer, is to amplify the energy dose within the tumour in the liver to improve the result from treatment.

    The nanopaticles were administered by intra-tumoural (IT) injection and activated by high precision radiation therapy.

    Patients received a NBTXR3 dose equivalent to 10% of the tumour volume. The trial showed a good safety profile with no adverse events and no leakage on the healthy surrounding tissue.

    Next steps will to increase the dosage to test for safety and tolerance.

    Liver cancer is one of the hardest forms of the disease to treat as although it responds well to radiation therapy delivering the radioactive dose is complex.

    Elsa Borghi, Nanobiotix’s chief medical officer, said: “At this stage, the safety and feasibility data of NBTXR3 in liver cancers are excellent.

    “Observations are similar to the results of our more advanced trials: Soft Tissue Sarcoma and Head and Neck cancers.

    “This is significant because these trials cover very different patient and disease profiles.

    “Based on the information gathered to date, we anticipate that by the end of this phase, we will have identified the appropriate conditions to use NBTXR3 in these patients populations.

    “Once again, all transferability data show the potential of broad applicability of NBTXR3 for use with radiotherapy in the treatment of solid tumors.”

    Nanobiotix’s nanopaticle treatment, NBTXR3 is injected into cancerous tumours where it absorbs the ionizing radiation delivered by radiotherapy and magnifies its effect locally. This shrinks the tumour making it easier to remove during surgery.
  18. [verwijderd] 27 januari 2017 13:02
    16.81 +0.81 (5.06%)

    NanoBiotix has adopted a novel approach to treating cancer based on hafnium oxide nanoparticles
    picture of scanner
    Nanobiotix's technology boosts radiotherapy's effectiveness
    Nanobiotix SA (EPA:NANO) can double in value when the results of key trials of its cancer treating technology start to come through this year believes Bryan Garnier.

    The French broker has started coverage of the nano-technology pioneer with a buy recommendation and target price for the Euronext-listed shares of €35. That compares to €16.80 currently.

    Nanobiotix’s proprietary technology, NanoXray or NBTX R3, enhances radiotherapy energy to provide a more efficient treatment for cancer patients and trials are underway in a number of cancers.

    “We expect significant clinical newsflow for NBTX R3 in soft-tissue sarcoma (interim read-out of Phase II/III) and head & neck cancer (follow-up of Phase I/II trial),” said the broker.

    “Following that, we believe the share price should remain underpinned by: A CE marking obtained for Europe and a partnership agreement signed with a big pharma group.“

    NanoBiotix has adopted a novel approach to treating cancer based on hafnium oxide nanoparticles to boost the effectiveness of radiotherapy or RTx.

    Raditotherapy doses are targeted much more precisely with the technology, reducing the damage to surrounding healthy tissue and shrinking tumours so they can be more easily removed by surgery.

    NBTX R3, the most advanced product, is currently being tested in indications accessible to intra-tumour injections such as liver, prostate cancers as well as head & neck and soft tissue sarcomas.

    The current RTx market is already sizeable (50-60% of cancer patients are already treated with this modality) says Bryan Garnier, but it believes that Nanobiotix should not only occupy a privileged position in it, but can also contribute to its expansion in two phases.

    “Firstly, by demonstrating a significant therapeutic benefit in indications where RTx is little used for the moment (like liver cancers).

    “Then, in view of the multiple synergies between its platform and agents destined for treatment of more advanced tumours/metastasis, such as immunotherapies and a number of targeted new therapies (in particular PARP inhibitors). “

    First news will be the interim read-out of the Phase II/III trial assessing NBTX R3 in soft-tissue sarcoma (STS) that is due mid-year.

    If this goes well, Bryan Garnier sees a first commercial approval during the third quarter and is hopeful as pathological response data obtained in a previous Phase I/II trial was encouraging.

    An update on the Phase I/II in the head & neck trial may coincide with US cancer body ASCO‘s congress in June it suggests.

  19. Omnius 7 maart 2017 09:45
    www.nanobiotix.com/download/news_en/2...

    NANOBIOTIX TO PRESENT PRECLINICAL DATA ON NANOPARTICLE RADIOENHANCER NBTXR3
    AT THE AACR ANNUAL MEETING 2017
    ? Antitumor efficacy of NBTXR3 in different types of tumors - in vivo preclinical data
    ? Antitumor efficacy of NBTXR3 when combined with chemotherapy - in vitro and in vivo data
    Paris, France and Cambridge, Massachusetts, March 7, 2017 – NANOBIOTIX (Euronext: NANO – ISIN:
    FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment
    of cancer, today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor
    efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in
    combination with chemotherapy, in both in vitro and in vivo studies. These data will be presented at the American
    Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C (April 1-5, 2017).
    A key part of the non-clinical development stands in building strategies to use NBTXR3 product across oncology
    as a single agent and in combination with other cancer treatments modalities. An increasing number of cancer
    models including patient’s tumor fragments have been evaluated in vitro and in vivo, with NBTXR3 and
    radiotherapy, increasing evidence of transferability of antitumor effects within very diverse tumors.
    “These NBTXR3 preclinical data highlight the Nanobiotix’ nanoparticles potential to treat different types of
    cancers” said Laurent Levy, CEO of Nanobiotix. “These results reinforce the rationale and level of scientific
    evidence to reach our long-term goal development of NBTXR3 in most cancer patients candidates to radiation
    treatment.”
    “Hafnium oxide nanoparticles (NBTXR3), a novel radiation enhancer achieves marked antitumor efficacy
    across five tumor types” Abstract number :17-A-2547
    Nanobiotix will present data illustrating the marked anti-tumor efficacy of NBTXR3 with radiotherapy, in in vivo
    conditions. NBTXR3 showed superiority when compared to the sole use of radiation in soft tissue sarcoma,
    prostate, head & neck, colorectal and lung cancer models including patient’s tumor fragment of prostate
    adenocarcinoma. These studies also showed NBTXR3 to have intratumor persistence of nanoparticles over time
    in all evaluated cancer types. In addition, animals tolerated the treatment very well.
    “The radioenhancer NBTXR3 brings anticancer efficacy to the cisplatin-based chemoradiation in vitro and in
    vivo” Abstract number :17-A-1065
    Nanobiotix will also present data highlighting the signs of NBTXR3’s antitumor efficacy when combined with
    cisplatin-based chemoradiation both in vitro and in vivo. Cisplatin is a cytotoxic agent that inhibits DNA repair of
    sub-lethal damage from irradiation. Chemoradiation of this type is currently the primary treatment for patients
    with high-risk head and neck cancers, cervix and non-small cell lung cancers. Nanobiotix’ in vivo and in vitro
    results revealed that adding NBTXR3 significantly improves the anticancer effect of the chemoradiation. This
    research was performed in collaboration with Professor Bo Lu, from the Cancer Center of Thomas Jefferson
    University in Philadelphia, PA
524 Posts
Pagina: «« 1 ... 22 23 24 25 26 27 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 874,02 -0,09%
EUR/USD 1,0697 -0,05%
FTSE 100 8.040,38 -0,06%
Germany40^ 18.086,70 -0,28%
Gold spot 2.316,11 -0,25%
NY-Nasdaq Composite 15.712,75 +0,10%

Stijgers

VIVORY...
+24,31%
ASMI
+10,99%
BESI
+4,08%
NX FIL...
+3,85%
TomTom
+3,80%

Dalers

ALLFUN...
-11,00%
ING
-5,96%
Flow T...
-2,94%
WDP
-2,89%
RELX
-2,04%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!